HCV therapeutics (Rigel)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameHCV therapeutics (Rigel)
Drug Alias NameHCV therapeutics (RiboGene)hepatitis C therapeutics (RiboGene)HCV therapeutics (Questcor/Rigel)hepatitis C therapeutics (Rigel)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesQuestcor Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesQuestcor Pharmaceuticals IncRigel Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A